Deletions of chromosomal band 9p21 have been detected in various tumor types as well as in more than 20% of acute lymphoblastic leukemia (ALL). These deletions frequently include the entire interferon (FM gene cluster as well as the methylthioadenosine phosphorylase (MTAP) gene. Recently, the CDKN2 gene MTS l, CDK41) was proposed as a candidate tumor-suppressor gene on 9p21 because it is frequently deleted in cell lines derived from multiple tumor types. To determine if CDKN2or another closely related gene on 9p is the target of 9p deletions in ALL and other hematologic malignancies, we analyzed 20 primary patient samples (13 ALL, 2 acute myeloid leukemias [AMLI, and 5 non-Hodgkin's lymphomas [NHLI) with 9p rearrangements using Southern blot analysis, fluorescence in situ hybridization (FISH), and single-strand conformation polymorphism (SSCP) for alterations of CDKN2. Homozygous deletions of the CDKN2ICDKN2B (p13 region were detected in 10 cases (50%; 6 ALL, 2 AML, and 2 NHL). In 1 additional case, the HE MALIGNANT transformation of tumor cells is known to be driven by the accumulation of various genetic alterations, including numerical and structural chromosomal alterations. Among the specific alterations associated with neoplasms, the loss of tumor-suppressor genes has been recognized as an important component. However, at present, deletions or mutations of the two commonly inactivated tumor-suppressor genes, TP53 and RBI, have been detected only in the minority of patients with acute lymphoblastic leukemia (ALL).'-* In contrast, cytogenetic deletions of chromosomal band 9p21 have been detected in 10% to 15% of ALL cases, indicating the presence of a novel tumorsuppressor gene in this r e g i~n .~.~ Using molecular analysis, the interferon (IFN) gene cluster located on 9p21 was found to be deleted in 43% of leukemia derived cell lines and 29% of primary leukemia ~amples.~.' Recently, the CDKN2 gene (p16'NK4A, MTS I, CDK41) that encodes an inhibitor of the cyclin-dependent kinase 4 has been found to be homozygously deleted in cell lines from multiple tumor types and has been proposed as a candidate tumor-suppressor gene in this region.*-'' Homozygous deletions are common in primary tumors, but the frequency of point mutations of this gene in hematologic malignancies has been very low, suggesting that CDKN2 may not be the critically relevant gene on 9p." Moreover, the extent of the homozygous deletions on 9p has not been clearly delineated in primary tumors. We analyzed 20 hematologic malignancies with cytogenetically well-characterized 9p rearrangements to define the critical region of 9p. We hypothesized that the cytogenetically visible abnormalities of 9p on one chromosomal allele might unmask a mutant recessive allele of the tumor-suppressor gene on the cytogenetically normal homologue. Southern blot analysis was used to determine the frequency and size of these Sp deletions using four markers generated from a 2.8-Mb YAC contig on 9~21.'' The results were confirmed by interphase fluorescence in situ hybridization (FISH) analysis. The cases with loss of one allele were analyzed by intensity of the Southern blot band was significantly reduced, suggesting a CDKN2 deletion in a subpopulation of the malignant cells. No CDKN2 or CDKN2B rearrangements were seen. The IFN gene cluster was homozygously deleted in 2 of 15 (13%0) analyzed cases, whereas the MTAP gene was deleted in 6 of 15 cases (40%). In addition, hemizygous deletions of the CDKN2 region were identified in 6 ALL cases using interphase FISH. No point mutation of the coding region of CDKN2 was detected by SSCP in these cases. We conclude that CDKN2 is the most frequently homozygously deleted marker on 9p. The absence of point mutations in the coding region of CDKN2 in cases with hemizygous 9p deletions and the frequent codeletion of MTAP, CDKN2B, and other yet unidentified neighboring genes suggest that the simultaneous deletion of these genes may be necessary for the selective growth advantage of malignant cells. single-strand conformation polymorphism (SSCP) to detect point mutations of the remaining CDKN2 allele.
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MATERIALS AND METHODS

Patients.
The karyotypes of patients with hematologic malignancies referred to the Hematology/Oncology Cytogenetic Laboratory of the University of Chicago Medical Center between 1989 and 1994 were reviewed. Twenty cases with cytogenetic rearrangement of the short arm of chromosome 9 in at least 30% of the metaphase cells analyzed and for which material were available were selected. Cytogenetically, 7 cases had a rearrangement that involved no loss of band 9p2 1, 9 cases retained one copy, and 4 cases had homozygous deletions of chromosomal band 9p21. Each case ( tion enzyme HindIII, electrophoresed on a 1% agarose gel, and transferred to a nylon-based nitrocellulose membrane (Gene Screen plus; NEN, Boston, MA). DNA filters were hybridized with "Plabeled probes from 9p21 and exposed to x-ray film. The chromosomal localization of the 9p probes is shown in Fig 1. Probe MI .4
represents the 3' untranslated region of the methylthioadenosine phosphorylase gene (MTAP) that was recently cloned by our group and is located approximately 100 kb telomeric to CDKN2.I' D9S966 is 200 kb centromeric to CDKN2.I6 CDKN2 (cDNA) and CDKN2B @15) (exon 1) are located within 20 kb of one another.' Equal DNA loading was verified by visual inspection of ethidium bromidestained gels and by control hybridizations to a transferrin receptor probe located on chromosome 3." FISH. Mononuclear cells of patient samples, normal bone marrow, and peripheral blood cells had been grown in short-term culture, harvested using standard cell culture techniques, and stored in fixative for several years." YAC A88E10 (330 kb), later referred to as YAC 11, was obtained by screening the St Louis library with ZFNAl primers." The contig of 8 cosmids encompassing a 250-kb region around CDKN2 (COSpl6) was assembled by screening a flow-sorted human chromosome 9 library (Lawrence Livermore Laboratories, Livermore, CA) with probes from a YAC contig of the In previous experiments, a similar cosmid contig probe identified all homozygous deletions in leukemia-derived cell lines.*' YAC 284D6 (320 kb), later referred to as YAC 1012, from chromosomal band 8q22 was used as a control probe," pHuR98, a variant satellite 3 sequence from the centromere of chromosome 9, was used to determine the copy number of this chromosome.23 FISH probes were prepared using sequence-independent amplification (SIA), as previously d e s~r i b e d . *~~~~ The copy number of chromosome 8 was determined by a centromeric FISH probe CEP 8 Spectrum Orange (Imagenetics, Framingham, MA). Two-color FISH with a YAC or cosmid probe and a centromeric probe was performed as previously described." Briefly, the hybridization solution contained approxi- were analyzed by SSCP. HL60, a myeloid cell line with a known point mutation in exon 2 (nucleotide 232: C --t T), was included as a positive control?' CDKN2 exons 1 and 2 were radiolabeled with 32P-dCTP using polymerase chain reaction using primers 2F and 1108F or 42F and 551R. as described previously.8 The amplification product was digested with Sac II and ApuL1, respectively, denatured, and run on a 4 0 % polyacrylamide gel under three different conditions (at room temperature, with 10% glycerol, and at 4°C).
RESULTS
Southern blot analysis. In 15 cases, DNA was available for Southern blot analysis. Homozygous deletions on 9p were detected in 8 cases (5 ALL, 1 AML, and 2 NHL). CDKN2 and CDKN2B were deleted in 8 cases (53%), D9S966 in 7 cases (47%), and M1.4 in 6 cases (40%) ( Table   2 and Fig 2) . Patient no. 3 had the smallest deletion detectable by the markers used, which included CDKN2 and CDKN2B but did not involve the flanking molecular markers.
In comparison, cytogenetic analysis detected homozygous deletions of 9p21-22 in only 2 of these cases (nos. 15 and 19), loss of one allele in 4 cases, and no loss of 9p21 in 2 of the 8 cases with homozygous 9p deletions detected by Southern blot. Thus, in the majority of cases the deletion was submicroscopic in one of the chromosome 9 homologues.
One case showed a significant reduction in the intensity of the Southern blot bands (no. 2 in Fig 2) . Only 51% of the metaphase cells from the bone marrow had a clonal abnormality of 9p. Thus, the Southern blot data likely represent a homozygous CDKN2 deletion in a subpopulation of cells. However, the Southern blot data are also compatible with a hemizygous deletion in the vast majority of the malignant cells. Unfortunately, there was no material available for FISH analysis.
Interphase FISH analysis. To determine the reliability of the FISH probes used in this study, we performed 10 test hybridizations of peripheral blood cells and five hybridizations of bone marrow cells from normal individuals with each probe." Both cosmid contig and YAC probes showed an almost identical distribution of signals per cell comparable to previously published results for centromeric probes. In 500 nuclei scored, 2 signals were detected in 94% to 97% of the cells. Interphase FISH analysis was performed on 15 patient samples. Homozygous deletions of COSpl6 were detected in 6 cases (3 ALL, 2 AML, and 1 NHL; Table 2 ), 4 of whom also showed homozygous deletions on Southern blot analysis ( Table 2) . Two of the patients had material for FISH studies but not for molecular studies. Cytogenetic analysis detected homozygous deletions of 91321-22 in 3 cases and loss of only one allele in 3 of the 6 cases with homozygous 9p deletions detected by FlSH (Table 2) . However, in all samples, the percentage of cells with 9p deletions detected by FlSH correlated closely with the percentage of metaphase cells with 9p rearrangements detected by cytogenetic analysis. In the cases with homozygous 9p deletion, 87.7% ? 7.3% of the cells showed no COSp16 signal, whereas 94.3% ? 2.7% of the cells retained all copies of the control YAC on chromosome 8 ( Figs 3A and 4) . Interphase FISH with COSpl6 identified all homozygous deletions detected by molecular analysis. However, 4 cases with homozygous deletion detected by Southern blot had no material available for FISH studies. Both copies of the IFN region (YAC I I ) were deleted in 2 ALL cases.
Hemizygous deletions of the CDKN2ICDKN2B region were detected by interphase FISH in 6 ALL cases (Fig 3B) . Cytogenetic analysis had predicted a loss of one copy of chromosomal band 9p21 in 4 of these cases and no loss of 9p21 in 2 cases (Table 2 ). We could not detect these hemizygous deletions using Southern blot analysis, probably because only subpopulations of cells (43% to 86% of interphase cells) were involved. In addition, molecular analysis did not detect any homozygous deletion or rearrangements of other markers in the region (M1.4 or D9S966) in these cases. In summary, combined interphase FlSH and Southern blot analysis detected CDKN2 deletions in all 13 ALL cases (100%; 7 homozygous and 6 hemizygous deletions), in both cases of AML (100%; homozygous deletions), and in 2 of 5 NHL cases (40%; homozygous deletions). The two deletions in NHL were observed in lymphomas of the diffuse large-cell subtype. Thus, 17 of our 20 cases (85%) had genomic 9p aberrations that included CDKN2. This higher deletion rate when compared with the cytogenetic analysis (65%; 4 homozygous and Y hemizygous deletions) reflects the detection of submicroscopic deletions by our combined techniques of interphase FISH and Southern blot analysis.
SSCP. Five of the 6 ALL cases with hemizygous CDKN2 deletions had DNA available for SSCP analysis. We used HL60, a myeloid cell line with a known point mutation in exon 2 (CDKN2), as control. We could not detect any abnormal SSCP bands in the 5 patient samples, suggesting the absence of point mutations in these samples (Table 2 and Fig 5) .
DISCUSSION
Losses of chromosomal material in tumor cells often indicate the localization of putative tumor-suppressor genes. In leukemia-derived cell lines, the frequency of 9p deletions is 38% to 88%. and CDKN2 has been shown to define the smallest region of deleti~n.~.".*~.'" Moreover, in one myeloid cell line (HL60) with a hemizygous 9p deletion, a point mutation within the coding region of CDKN2 could be detected in the remaining allele, resulting in a truncation of p16 protein." About 90% of the deletions that affect CDKN2 and CDKN2B are homozygous and often extend over 500 kb or more.31 However, point mutations in CDKN2 are rare in hematologic malignancies, which has made the candidacy of CDKN2 controversial. Our group previously detected IFN gene deletions in 43% of leukemia-derived cell lines and in 29% of the primary leukemia samples.'.' Our refined mapping in leukemic cell lines has identified a critical region on Yp21 of approximately 300 kb encompassing CDKN2." In the present study of 20 primary hematologic malignancies with cytogenetically detected rearrangements of Yp. CDKN2 was included in genomic alterations in 85% of the cases. This finding confirms that the CDKN2 region is the likely target of 9p deletions in these hematologic malignancies because I0 of 17 cases (59%) of deletions detected by molecular analysis affected an apparently cytogenetically normal band 9p2 I . In addition to homozygous deletions, we detected hemizygous deletions in 6 patients or 30% of our samples. Southern blot analysis was not able to detect these hemizygous deletions because of contamination with normal cells. Previous region of CDKN2 in these cases very There remains a possibility that mutations may be found in the promotor region or other important regulatory regions in the noncoding part of CDKN2. Alternatively, the loss of one allele with 50% reduction in the gene dosage may be sufficient for a growth advantage of the malignant cell. This hypothesis remains to be proven. However, neither scenario explains the predominance of large homozygous deletions in our series. The absence of point mutations of CDKN2 in the cases with hemizygous 9p deletions may suggest that CDKN2 is not the critical target of 9p deletions in these cases. In other primary tumors, such as glioblastoma, point mutations of CDKN2 are also rare.33-36 Recently, Quesnel et alii detected only one CDKNZ point mutation in 88 cases of ALL. These findings have led to the suggestion that the inactivation of either CDKN2B. which was included in all our 9p deletions, or other yet unidentified neighboring genes may be important for the malignant phenotype as well. However, we have found that CDKN2R is not deleted in 2 of 16 leukemic cell lines with CDKN2 deletion." Thus, the smallest commonly deleted region that we could define in leukemia-derived cell lines and these primary tumors is bounded on the telomeric side by the 3' end of MTAP (probe M1.4) and on the centromeric side by CDKN2B. This 120-kb region is included in COSpl6; whether additional genes can be identified in this region remains to be determined. Nevertheless, the frequent codeletion of MTAP, an enzyme involved in the salvage pathway of purine metabolism, could be of significant clinical relevance in hematologic malignancies.
Our study does not address the frequency of 9p deletions in different hematologic tumors. In agreement with the findings of other studies, we detected most of the 9p deletions tween 9p deletions and a lymphomatous phenotype of T-ALL.3 However, 12 of our 13 ALL cases were B-ALL. In addition, we found homozygous 9p deletions in 2 of 3 cases with diffuse large-cell subtype of NHL. A homozygous 9p deletion was previously detected in a cell line derived from the diffuse large-cell type of NHL." This finding suggests that these two different histologic entities (ALL and diffuse large-cell lymphoma) are derived from a common precursor cell that is sensitive to the inactivation of genes in the CDKN2 region. The overall frequency of CDKN2 deletions in diffuse large-cell lymphoma remains to be determined.
Our results confirm that the CDKN2 region is the target of 9p rearrangements detected by cytogenetic analysis. The predominant mechanism of inactivation of CDKN2 is homozygous genomic deletion. No point mutations of CDKN2 were detected in cases with hemizygous deletions. Therefore, the deletion of other as yet unidentified genes that are tightly linked to CDKN2 may also be important. The critical region determined by our deletion mapping in these primary tumor samples as well as cell lines centers around CDKNZ and is bordered by MTAP and CDKN2B, but codeletion of these neighboring genes is frequent. Thus, a careful analysis of this region with respect to the different genes included in the 9p rearrangement is necessary. Only then will it be possible to accurately determine the clinical relevance of alterations of this complex region in hematologic malignancies. in ALL.21.29.37 Initial studies had suggested a correlation be-
